The Abramson Cancer Center facilitates interdisciplinary cancer research, education, and patient care. Its 299 members are drawn from 41 Departments and eight Schools of the University and have $120,755,622 million in research and training (annual direct costs), a 73% increase in the past five years, of which $111,281,669 is peer-reviewed and $56,709,782 is NCI funded (138% increase in the past five years). This includes 20 NIH P01s and seven P50s. John Glick, MD, has served as Director since 1985. Eleven Research Programs comprise the Cancer Center's three Divisions (Fundamental Research, Clinical Research, Cancer Control and Population Sciences). The Cancer Center supports 15 Shared Resources, five of which are new. The development of strong Research Programs and leading-edge Shared Resources, the recruitment of outstanding faculty in areas of priority, and the acquisition of additional research space have enabled the Cancer Center to realize its mission. An ongoing strategic planning process identifies future directions, while guiding current activities and resource allocations. A wide range of seminars and retreats as well as interdisciplinary laboratory space are among the ways in which the Cancer Center sucessfully facilitates interaction and collaboration. Developmental Funds are critical to faculty recruitment and the funding of innovative pilot projects with the potential for peer-reviewed funding, translational research initiatives, and Shared Resources. The Division of Cancer Control and Population Sciences has benefited from the recruitment of Caryn Lerman, PhD, as Associate Director and other significant faculty recruitments. The Clinical Research Division's progress is distinguished by innovative translational research in all Research Programs and a nationally recognized experimental therapeutics effort. In the basic sciences, leadership changes have led to greater activity in translational research and increased collaborations. The Cancer Center continues to meet Comprehensiveness guidelines, and was last approved in 1999.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Acosta, Jonuelle; Wang, Walter; Feldser, David M (2018) Off and back-on again: a tumor suppressor's tale. Oncogene 37:3058-3069
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571

Showing the most recent 10 out of 1047 publications